semindr

Olink Next Generation Proteomic Technology







Dr Slavé Petrovski, Vice President of AstraZeneca. Olink [®] Explore Data Stories from UK Biobank Pharma Proteomics Project: Transform biobank samples into actionable insights.


Dr Petrovski has a background in human genomics, population genetics, precision medicine and leading large-sale human genomic studies. He has been a key participant in UK Biobank Pharma Proteomics Project (UKB-PPP), and will share how next-generation proteomics is transforming biobank samples into actionable insights, thereby reshaping precision medicine.

Dr Cindy Lawley, Senior Director of Population Health, Olink Proteomics.

Proteomics as a bridge between genomics and human health.



Large studies combining both DNA & protein-based techniques are increasingly showing how proteomics can empower genomics, providing the link from genes to phenotypes to set a strong foundation for future healthcare development. Cindy Lawley will be sharing insights and highlights derived from the groundbreaking research conducted within the UK Biobank and other large cohort studies where proteo-genomic technology is being leveraged to identify potential biomarkers and new druggable targets.





Dr Clarissa Yates, CEO and Founder of Ketim Therapeutics, Brisbane. Are we there yet? Towards precision medicine for mental health: An insight using Olink proteomics.

Dr Clarissa Yates, CEO and Founder of Ketim Therapeutics, is a Brisbane-based mental health innovator with a PhD in Clinical Neuroscience from the University of Queensland. Leveraging AI, she's pioneering predictive blood based biomarkers for mental health disorders. With over a decade experience, Clarissa's research, published in prestigious journals like Nature Translational Psychiatry, aims to personalise treatments and revolutionise mental health care, starting with perinatal and postpartum depression.

Register via www.agrf.org.au/events